share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

諾和諾德 | 6-K：諾和諾德-股票回購計劃
美股sec公告 ·  06/03 23:05
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated this program on May 6, 2024, as part of a larger 12-month buyback plan worth up to DKK 20 billion, which began on February 6, 2024. From May 7 to August 5, 2024, Novo Nordisk is set to repurchase B shares for up to DKK 2.2 billion. As of May 31, 2024, the company has repurchased 9,366,795 B shares at an average price of DKK 865.36, totaling DKK 8,105,649,158. The recent transactions from May 27 to May 31, 2024, resulted in the acquisition of 196,393 B shares for a combined value of DKK 180,735,500, bringing the total shares repurchased under the program to 632,545. Novo Nordisk now holds 10,732,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated this program on May 6, 2024, as part of a larger 12-month buyback plan worth up to DKK 20 billion, which began on February 6, 2024. From May 7 to August 5, 2024, Novo Nordisk is set to repurchase B shares for up to DKK 2.2 billion. As of May 31, 2024, the company has repurchased 9,366,795 B shares at an average price of DKK 865.36, totaling DKK 8,105,649,158. The recent transactions from May 27 to May 31, 2024, resulted in the acquisition of 196,393 B shares for a combined value of DKK 180,735,500, bringing the total shares repurchased under the program to 632,545. Novo Nordisk now holds 10,732,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
領先的全球醫療保健公司諾和諾德（Novo Nordisk A/S）報告了其股票回購計劃的進展情況。該公司總部位於丹麥，於2024年5月6日啟動了此計劃，作為價值高達200億丹麥克朗的更大型為期12個月的回購計劃的一部分，該計劃始於2024年2月6日。從2024年5月7日至8月5日，諾和諾德將回購多達22億丹麥克朗的B股。截至2024年5月31日，該公司已經回購了9,366,795股B股，平均價格為865.36丹麥克朗，總價值為8,105,649,158丹麥克朗。從2024年5月27日至5月31日的最近交易導致獲得196,393股B股，合共價值為1.807億丹麥克朗，使該計劃回購的股份總數達到了632,545股。諾和諾德現在持有10,732,359股B股為庫藏股，佔股本的0.2％。該公司的股票在Copenhagen納斯達克和紐約證券交易所上市交易。
領先的全球醫療保健公司諾和諾德（Novo Nordisk A/S）報告了其股票回購計劃的進展情況。該公司總部位於丹麥，於2024年5月6日啟動了此計劃，作為價值高達200億丹麥克朗的更大型為期12個月的回購計劃的一部分，該計劃始於2024年2月6日。從2024年5月7日至8月5日，諾和諾德將回購多達22億丹麥克朗的B股。截至2024年5月31日，該公司已經回購了9,366,795股B股，平均價格為865.36丹麥克朗，總價值為8,105,649,158丹麥克朗。從2024年5月27日至5月31日的最近交易導致獲得196,393股B股，合共價值為1.807億丹麥克朗，使該計劃回購的股份總數達到了632,545股。諾和諾德現在持有10,732,359股B股為庫藏股，佔股本的0.2％。該公司的股票在Copenhagen納斯達克和紐約證券交易所上市交易。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。